Description
Etopozid (Etoposide) Concentrate for Infusions 20 mg/ml. 10 ml. (200 mg.) Vial №1
Composition
Active ingredient: Etoposide. Inactive ingredients may include citric acid, polysorbate 80, and sodium chloride.
Mechanism of Action
Pharmacological Properties: Etoposide exerts its anticancer effects by inhibiting topoisomerase II enzyme, leading to DNA damage and cell death in rapidly dividing cancer cells. This mechanism makes it an essential component of many chemotherapy regimens.
Indications for Use
Indications: Etopozid is indicated for the treatment of small cell lung cancer, testicular cancer, and other malignancies. It works by inhibiting topoisomerase II enzyme, leading to DNA damage in cancer cells.
Contraindications
Contraindications: Etopozid is contraindicated in patients with a known hypersensitivity to etoposide or any of the inactive ingredients in the formulation.
Side Effects
Etopozid may cause nausea, vomiting, and hair loss as common side effects. It is important to monitor blood counts regularly during etoposide therapy to assess for potential bone marrow suppression. Patients should be closely monitored for signs of infection or bleeding.
Usage Instructions
Dosage: The recommended dose of Etopozid concentrate for infusions is determined by the patient’s body surface area and the specific protocol used. It is administered intravenously by a healthcare professional.
Administration: Etopozid concentrate for infusions should only be administered by healthcare professionals experienced in the use of cytotoxic chemotherapy.
Benefits Compared to Analogues
Comparative Effectiveness: Etopozid has shown comparable effectiveness to other topoisomerase inhibitors in the treatment of various cancers. Its use in combination therapies has demonstrated improved outcomes in certain malignancies.
Suitable Patient Groups
Etopozid is suitable for adult patients with small cell lung cancer, testicular cancer, and other malignancies. Dosage adjustments may be necessary for elderly patients or those with renal or hepatic impairment.
Storage and Packaging
Etopozid should be stored according to the manufacturer’s instructions. The shelf life of the product is as indicated on the packaging. Each vial contains 10 ml of 20 mg/ml concentrate for infusion.
Clinical Evidence and Proven Effectiveness
Etoposide, the active ingredient in Etopozid, has been extensively studied for its efficacy in various cancer types. Research has shown that etoposide disrupts DNA synthesis in cancer cells, leading to cell death. Clinical trials have demonstrated the effectiveness of etoposide in combination with other chemotherapeutic agents in improving overall survival rates in cancer patients.
